322 related articles for article (PubMed ID: 26696549)
21. Utilization of p40 (ΔNp63) with p63 and cytokeratin 5/6 immunohistochemistry in non-small cell lung carcinoma fine-needle aspiration biopsy.
Collins BT; Wang JF; Bernadt CT
Acta Cytol; 2013; 57(6):619-24. PubMed ID: 24107322
[TBL] [Abstract][Full Text] [Related]
22. Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer.
Owen D; Sheffield BS; Ionescu D; Churg A
Hum Pathol; 2017 Feb; 60():82-85. PubMed ID: 27984124
[TBL] [Abstract][Full Text] [Related]
23. The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas.
El-Maqsoud NM; Tawfiek ER; Abdelmeged A; Rahman MF; Moustafa AA
Tumour Biol; 2016 Mar; 37(3):3123-34. PubMed ID: 26427663
[TBL] [Abstract][Full Text] [Related]
24. Use of dual-marker staining to differentiate between lung squamous cell carcinoma and adenocarcinoma.
Guo R; Tian Y; Zhang N; Huang H; Huang Y; Yang J
J Int Med Res; 2020 Apr; 48(4):300060519893867. PubMed ID: 31880186
[TBL] [Abstract][Full Text] [Related]
25. Contribution of immunohistochemistry in the differential diagnosis of non-small cell lung carcinomas on small biopsy samples.
Stojsic J; Jovanic I; Markovic J; Gajic M
J BUON; 2013; 18(1):176-87. PubMed ID: 23613404
[TBL] [Abstract][Full Text] [Related]
26. High frequency of coexpression of maspin with p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of the lung.
Choy B; Findeis-Hosey JJ; Li F; McMahon LA; Yang Q; Xu H
Int J Clin Exp Pathol; 2013; 6(11):2542-7. PubMed ID: 24228118
[TBL] [Abstract][Full Text] [Related]
27. p40 (ΔNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a review and comparative analysis.
Vogt AP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2014 May; 42(5):453-8. PubMed ID: 24166777
[TBL] [Abstract][Full Text] [Related]
28. The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.
Ao MH; Zhang H; Sakowski L; Sharma R; Illei PB; Gabrielson E; Askin F; Li QK
Hum Pathol; 2014 May; 45(5):926-34. PubMed ID: 24746197
[TBL] [Abstract][Full Text] [Related]
29. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas.
Stoll LM; Johnson MW; Gabrielson E; Askin F; Clark DP; Li QK
Cancer Cytopathol; 2010 Dec; 118(6):441-9. PubMed ID: 20830690
[TBL] [Abstract][Full Text] [Related]
30. Utility of TTF-1 and Napsin-A in the work-up of malignant effusions.
El Hag M; Schmidt L; Roh M; Michael CW
Diagn Cytopathol; 2016 Apr; 44(4):299-304. PubMed ID: 26799356
[TBL] [Abstract][Full Text] [Related]
31. IMP3 can predict aggressive behaviour of lung adenocarcinoma.
Beljan Perak R; Durdov MG; Capkun V; Ivcevic V; Pavlovic A; Soljic V; Peric M
Diagn Pathol; 2012 Nov; 7():165. PubMed ID: 23190601
[TBL] [Abstract][Full Text] [Related]
32. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies.
Warth A; Muley T; Herpel E; Meister M; Herth FJ; Schirmacher P; Weichert W; Hoffmann H; Schnabel PA
Histopathology; 2012 Dec; 61(6):1017-25. PubMed ID: 22882703
[TBL] [Abstract][Full Text] [Related]
33. Head-to-Head Comparison of p63 and p40 in Non-Neuroendocrine Carcinomas of the Tubal Gut.
Bakhshwin AM; Gordon IO; Brown KB; Liu X; Allende DS
Int J Surg Pathol; 2020 Dec; 28(8):835-843. PubMed ID: 32466705
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the expression levels of napsin A, thyroid transcription factor-1, and p63 in nonsmall cell lung cancer using cytocentrifuged bronchial brushings.
Aikawa E; Kawahara A; Hattori S; Yamaguchi T; Abe H; Taira T; Azuma K; Kage M
Cancer Cytopathol; 2011 Oct; 119(5):335-45. PubMed ID: 21717589
[TBL] [Abstract][Full Text] [Related]
35. The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma.
Roh MH; Schmidt L; Placido J; Farmen S; Fields KL; Courey AJ; Arenberg DA; Knoepp SM
Diagn Cytopathol; 2012 Nov; 40(11):949-55. PubMed ID: 21500373
[TBL] [Abstract][Full Text] [Related]
36. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.
Tsuta K; Tanabe Y; Yoshida A; Takahashi F; Maeshima AM; Asamura H; Tsuda H
J Thorac Oncol; 2011 Jul; 6(7):1190-9. PubMed ID: 21623236
[TBL] [Abstract][Full Text] [Related]
37. Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer.
Kriegsmann K; Cremer M; Zgorzelski C; Harms A; Muley T; Winter H; Kazdal D; Warth A; Kriegsmann M
Pathology; 2019 Apr; 51(3):240-245. PubMed ID: 30798982
[TBL] [Abstract][Full Text] [Related]
38. Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer.
Koyi H; Brandén E; Kasim I; Wilander E
Anticancer Res; 2018 Jun; 38(6):3341-3346. PubMed ID: 29848682
[TBL] [Abstract][Full Text] [Related]
39. New immunohistochemical markers in the differential diagnosisof nonsmall cell lung carcinoma.
Bir F; Çeliker D; Evyapan BF; Yaren A; Edirne T
Turk J Med Sci; 2016 Dec; 46(6):1854-1861. PubMed ID: 28081338
[TBL] [Abstract][Full Text] [Related]
40. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.
Micke P; Mattsson JS; Djureinovic D; Nodin B; Jirström K; Tran L; Jönsson P; Planck M; Botling J; Brunnström H
J Thorac Oncol; 2016 Jun; 11(6):862-72. PubMed ID: 26872818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
